- Home
- IIM vs RIGL Comparison
IIM vs RIGL Comparison
Compare IIM & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIM
- RIGL
- Stock Information
- Founded
- IIM 1993
- RIGL 1996
- Country
- IIM United States
- RIGL United States
- Employees
- IIM N/A
- RIGL N/A
- Industry
- IIM Investment Managers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- IIM Finance
- RIGL Health Care
- Exchange
- IIM Nasdaq
- RIGL Nasdaq
- Market Cap
- IIM 582.9M
- RIGL 486.4M
- IPO Year
- IIM N/A
- RIGL 2000
- Fundamental
- Price
- IIM $11.79
- RIGL $17.09
- Analyst Decision
- IIM
- RIGL Buy
- Analyst Count
- IIM 0
- RIGL 5
- Target Price
- IIM N/A
- RIGL $34.80
- AVG Volume (30 Days)
- IIM 122.2K
- RIGL 203.8K
- Earning Date
- IIM 01-01-0001
- RIGL 11-07-2024
- Dividend Yield
- IIM 4.63%
- RIGL N/A
- EPS Growth
- IIM N/A
- RIGL N/A
- EPS
- IIM 0.02
- RIGL 0.22
- Revenue
- IIM N/A
- RIGL $157,374,000.00
- Revenue This Year
- IIM N/A
- RIGL $48.98
- Revenue Next Year
- IIM N/A
- RIGL $14.43
- P/E Ratio
- IIM $591.50
- RIGL $77.18
- Revenue Growth
- IIM N/A
- RIGL 21.65
- 52 Week Low
- IIM $9.94
- RIGL $7.48
- 52 Week High
- IIM $12.32
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- IIM 24.40
- RIGL 30.82
- Support Level
- IIM $11.78
- RIGL $16.68
- Resistance Level
- IIM $12.70
- RIGL $19.80
- Average True Range (ATR)
- IIM 0.13
- RIGL 1.53
- MACD
- IIM -0.08
- RIGL -1.05
- Stochastic Oscillator
- IIM 1.09
- RIGL 3.66
About IIM Invesco Value Municipal Income Trust
Invesco Value Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide common shareholders with current income which is exempt from federal income tax.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.